JP2013545810A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545810A5
JP2013545810A5 JP2013544718A JP2013544718A JP2013545810A5 JP 2013545810 A5 JP2013545810 A5 JP 2013545810A5 JP 2013544718 A JP2013544718 A JP 2013544718A JP 2013544718 A JP2013544718 A JP 2013544718A JP 2013545810 A5 JP2013545810 A5 JP 2013545810A5
Authority
JP
Japan
Prior art keywords
alkyl
pyridinyl
phenyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013544718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545810A (ja
JP6097998B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/064770 external-priority patent/WO2012082817A1/en
Publication of JP2013545810A publication Critical patent/JP2013545810A/ja
Publication of JP2013545810A5 publication Critical patent/JP2013545810A5/ja
Application granted granted Critical
Publication of JP6097998B2 publication Critical patent/JP6097998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013544718A 2010-12-16 2011-12-14 ロイコトリエン生成のビアリールアミドインヒビター Active JP6097998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42366710P 2010-12-16 2010-12-16
US61/423,667 2010-12-16
PCT/US2011/064770 WO2012082817A1 (en) 2010-12-16 2011-12-14 Biarylamide inhibitors of leukotriene production

Publications (3)

Publication Number Publication Date
JP2013545810A JP2013545810A (ja) 2013-12-26
JP2013545810A5 true JP2013545810A5 (cg-RX-API-DMAC7.html) 2015-02-12
JP6097998B2 JP6097998B2 (ja) 2017-03-22

Family

ID=45478495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013544718A Active JP6097998B2 (ja) 2010-12-16 2011-12-14 ロイコトリエン生成のビアリールアミドインヒビター

Country Status (4)

Country Link
US (1) US9073895B2 (cg-RX-API-DMAC7.html)
EP (1) EP2651930B1 (cg-RX-API-DMAC7.html)
JP (1) JP6097998B2 (cg-RX-API-DMAC7.html)
WO (1) WO2012082817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093508A2 (en) * 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
KR20140138243A (ko) * 2012-02-28 2014-12-03 피라말 엔터프라이지즈 리미티드 G 단백질 연결 수용체 작용물질로서의 페닐알칸산 유도체
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
WO2014141187A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
KR20160055170A (ko) * 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
CR20170094A (es) 2014-09-10 2017-05-08 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
LT3191450T (lt) 2014-09-10 2019-06-10 Glaxosmithkline Intellectual Property Development Limited Piridono dariniai kaip transfekcijos metu pertvarkyti (ret) kinazės inhibitoriai
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
CA2970011C (en) * 2014-12-24 2021-08-03 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2017232610B2 (en) * 2016-03-16 2021-07-22 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
PL3484855T3 (pl) 2016-07-18 2022-06-20 Oat Agrio Co., Ltd. Nowy związek benzyloamidowy, sposób jego wytwarzania i środek roztoczobójczy
KR20190040068A (ko) * 2016-08-29 2019-04-16 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 질환의 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 저해제
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN117777121A (zh) 2016-10-24 2024-03-29 詹森药业有限公司 化合物及其用途
US10093664B2 (en) 2016-12-08 2018-10-09 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
EP3694503B1 (en) * 2017-10-09 2023-08-02 Merck Sharp & Dohme LLC Novel substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11319283B2 (en) 2017-10-09 2022-05-03 Merck Sharp & Dohme Corp. Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CA3092362A1 (en) * 2017-10-19 2019-04-25 Tempest Therapeutics, Inc. Picolinamide compounds
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3710444B1 (en) * 2017-11-14 2023-04-12 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3717459A1 (en) * 2017-11-30 2020-10-07 Step Pharma S.A.S. Compounds
US11505547B2 (en) 2017-11-30 2022-11-22 Step Pharma S.A.S. Compounds
CN112312913B (zh) * 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
SI3802517T1 (sl) 2018-06-07 2023-04-28 Idorsia Pharmaceuticals Ltd Alkoksi-substituirani piridinilni derivati kot antagonisti receptorja LPA1 in njihova uporaba pri zdravljenju fibroze
AU2019413360B2 (en) 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
SG11202108079RA (en) 2019-01-24 2021-08-30 Yumanity Therapeutics Inc Compounds and uses thereof
DK3980411T3 (da) 2019-06-04 2025-10-13 Step Pharma S A S N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamid som en human ctps1-inhibitor til behandling af proliferative sygdomme
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2021252555A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
CN114075139B (zh) * 2020-08-14 2025-09-26 广东东阳光药业股份有限公司 五元杂芳环类化合物及其在药物中的应用
JP7775288B2 (ja) * 2020-08-18 2025-11-25 ハチメド リミテッド ピリミジノン化合物およびその使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126691A (en) * 1968-03-27 1978-11-21 Ciba-Geigy Corporation Tertiary aminoacids
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
GB9010404D0 (en) * 1990-05-09 1990-06-27 Pfizer Ltd Therapeutic agents
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
HK1048634B (zh) 1999-08-06 2005-09-30 詹森药业有限公司 非类固醇类的il-5抑制剂,其制备的方法以及包含该抑制剂的医药组合物
SK1812002A3 (en) * 1999-08-12 2003-02-04 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US20040019046A1 (en) * 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US8759335B2 (en) * 2004-01-30 2014-06-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1814877B1 (en) * 2004-10-18 2009-03-11 Merck & Co., Inc. Diphenyl substituted alkanes as flap inhibitors
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP1919875A2 (en) * 2005-06-21 2008-05-14 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
SI2455382T1 (sl) * 2005-12-13 2017-03-31 Incyte Holdings Corporation S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
US7530476B2 (en) * 2006-04-10 2009-05-12 Precision Valve Corporation Locking aerosol dispenser
CN101466677A (zh) 2006-04-11 2009-06-24 默克公司 二芳基取代的烷烃
CA2666686A1 (en) * 2006-09-01 2008-03-13 Merck & Co., Inc. Inhibitors of 5-lipoxygenase activating protein (flap)
CA2683948A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2008156721A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Diphenyl substituted alkanes
CA2702225A1 (en) 2007-10-10 2009-04-16 Merck Sharp & Dohme Corp. Diphenyl substituted cycloalkanes
CN101896461A (zh) * 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
US8546422B2 (en) * 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
DK2607348T3 (da) * 2009-03-31 2021-05-25 Renascience Inc Inhibitor af plasminogenaktivatorinhibitor-1
CN102470127A (zh) * 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
SG187549A1 (en) * 2010-08-16 2013-03-28 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production

Similar Documents

Publication Publication Date Title
JP2013545810A5 (cg-RX-API-DMAC7.html)
JP2013536235A5 (cg-RX-API-DMAC7.html)
JP2013542994A5 (cg-RX-API-DMAC7.html)
JP2011525192A5 (cg-RX-API-DMAC7.html)
JP2015503621A5 (cg-RX-API-DMAC7.html)
JP2009263394A5 (cg-RX-API-DMAC7.html)
JP2014506907A5 (cg-RX-API-DMAC7.html)
JP2014507455A5 (cg-RX-API-DMAC7.html)
JP2013542218A5 (cg-RX-API-DMAC7.html)
JP2015503620A5 (cg-RX-API-DMAC7.html)
JP2019034943A5 (cg-RX-API-DMAC7.html)
JP2013534245A5 (cg-RX-API-DMAC7.html)
JP2017514830A5 (cg-RX-API-DMAC7.html)
JP2011168609A5 (cg-RX-API-DMAC7.html)
JP2010506850A5 (cg-RX-API-DMAC7.html)
JP2015512931A5 (cg-RX-API-DMAC7.html)
JP2017512779A5 (cg-RX-API-DMAC7.html)
HRP20140723T1 (hr) Postupak za proizvodnju rosuvastatina
JP2016512834A5 (cg-RX-API-DMAC7.html)
BRPI0714840A2 (pt) composto, processo para a preparaÇço e uso do mesmo, composiÇço farmacÊutica, processo para a preparaÇço da mesma, e, produto
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2013521291A5 (cg-RX-API-DMAC7.html)
JP2017523209A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
JP2013537908A5 (cg-RX-API-DMAC7.html)